• Je něco špatně v tomto záznamu ?

Metformin Affects Cardiac Arachidonic Acid Metabolism and Cardiac Lipid Metabolite Storage in a Prediabetic Rat Model

D. Miklankova, I. Markova, M. Hüttl, I. Zapletalova, M. Poruba, H. Malinska

. 2021 ; 22 (14) : . [pub] 20210719

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025335

Grantová podpora
IN 00023001 Ministerstvo Zdravotnictví Ceské Republiky
IGA_LF_2021_013 Ministerstvo Zdravotnictví Ceské Republiky

Metformin can reduce cardiovascular risk independent of glycemic control. The mechanisms behind its non-glycemic benefits, which include decreased energy intake, lower blood pressure and improved lipid and fatty acid metabolism, are not fully understood. In our study, metformin treatment reduced myocardial accumulation of neutral lipids-triglycerides, cholesteryl esters and the lipotoxic intermediates-diacylglycerols and lysophosphatidylcholines in a prediabetic rat model (p < 0.001). We observed an association between decreased gene expression and SCD-1 activity (p < 0.05). In addition, metformin markedly improved phospholipid fatty acid composition in the myocardium, represented by decreased SFA profiles and increased n3-PUFA profiles. Known for its cardioprotective and anti-inflammatory properties, metformin also had positive effects on arachidonic acid metabolism and CYP-derived arachidonic acid metabolites. We also found an association between increased gene expression of the cardiac isoform CYP2c with increased 14,15-EET (p < 0.05) and markedly reduced 20-HETE (p < 0.001) in the myocardium. Based on these results, we conclude that metformin treatment reduces the lipogenic enzyme SCD-1 and the accumulation of the lipotoxic intermediates diacylglycerols and lysophosphatidylcholine. Increased CYP2c gene expression and beneficial effects on CYP-derived arachidonic acid metabolites in the myocardium can also be involved in cardioprotective effect of metformin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025335
003      
CZ-PrNML
005      
20211207141517.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22147680 $2 doi
035    __
$a (PubMed)34299301
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Miklankova, Denisa $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic
245    10
$a Metformin Affects Cardiac Arachidonic Acid Metabolism and Cardiac Lipid Metabolite Storage in a Prediabetic Rat Model / $c D. Miklankova, I. Markova, M. Hüttl, I. Zapletalova, M. Poruba, H. Malinska
520    9_
$a Metformin can reduce cardiovascular risk independent of glycemic control. The mechanisms behind its non-glycemic benefits, which include decreased energy intake, lower blood pressure and improved lipid and fatty acid metabolism, are not fully understood. In our study, metformin treatment reduced myocardial accumulation of neutral lipids-triglycerides, cholesteryl esters and the lipotoxic intermediates-diacylglycerols and lysophosphatidylcholines in a prediabetic rat model (p < 0.001). We observed an association between decreased gene expression and SCD-1 activity (p < 0.05). In addition, metformin markedly improved phospholipid fatty acid composition in the myocardium, represented by decreased SFA profiles and increased n3-PUFA profiles. Known for its cardioprotective and anti-inflammatory properties, metformin also had positive effects on arachidonic acid metabolism and CYP-derived arachidonic acid metabolites. We also found an association between increased gene expression of the cardiac isoform CYP2c with increased 14,15-EET (p < 0.05) and markedly reduced 20-HETE (p < 0.001) in the myocardium. Based on these results, we conclude that metformin treatment reduces the lipogenic enzyme SCD-1 and the accumulation of the lipotoxic intermediates diacylglycerols and lysophosphatidylcholine. Increased CYP2c gene expression and beneficial effects on CYP-derived arachidonic acid metabolites in the myocardium can also be involved in cardioprotective effect of metformin.
650    _2
$a zvířata $7 D000818
650    _2
$a kyselina arachidonová $x metabolismus $7 D016718
650    _2
$a bazální metabolismus $x účinky léků $7 D001481
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a kardiotonika $x farmakologie $7 D002316
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a desaturasy mastných kyselin $x metabolismus $7 D044943
650    _2
$a srdce $x účinky léků $7 D006321
650    _2
$a hyperlipoproteinemie typ IV $x farmakoterapie $x metabolismus $7 D006953
650    _2
$a hypoglykemika $x farmakologie $7 D007004
650    _2
$a mediátory zánětu $x krev $7 D018836
650    _2
$a metabolismus lipidů $x účinky léků $7 D050356
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metformin $x farmakologie $7 D008687
650    _2
$a myokard $x metabolismus $7 D009206
650    _2
$a prediabetes $x farmakoterapie $x metabolismus $7 D011236
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a Markova, Irena $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Hüttl, Martina $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Zapletalová, Iveta $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic $7 xx0267200
700    1_
$a Poruba, Martin $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Malinska, Hana $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 14 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34299301 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211207141515 $b ABA008
999    __
$a ok $b bmc $g 1714402 $s 1145842
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 14 $e 20210719 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a IN 00023001 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a IGA_LF_2021_013 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace